512 completed. 512 Phase 1, 145 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 512 | Completed 512 |
| Phase 2 | 145 | Completed 145 |
Follow Urologic Neoplasms: new trials by email Literature Review of Urologic Neoplasms trials Research Report on Urologic Neoplasms
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of MK-4700 Alone or With Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors (MK-4700-001) MK-4700, Pembrolizumab - Malignant Neoplasm | Phase 1 | Completed | Merck Sharp & Dohme LLC | 5 | 2025-04-23 | 2026-03-16 |
| A Study to Evaluate the Safety and Dosimetry of 68Ga-OncoCAIX in Patients With CAIX-positive Cancer [68Ga]Ga-OncoCAIX - Clear Cell Renal Cell Carcinoma (ccRCC) | Phase 1 | Completed | Philogen S.p.A. | 20 | 2025-04-16 | 2026-01-13 |
| A Phase 1/1b Study of ZH9 Treatment in Patients With Non-Muscle Invasive Bladder Cancer ZH9 - NMIBC, High Risk NMIBC | Phase 1 | Completed | Prokarium Ltd | 22 | 2024-01-08 | 2026-10-14 |
| Study of DF6215 in Patients With Advanced Solid Tumors DF6215, pembrolizumab, KEYTRUDA® - Solid Tumor, Adult, Solid Tumor Cancer | Phase 1 | Completed | Dragonfly Therapeutics | 35 | 2023-11-28 | 2026-03-18 |
| Safety, PK and Efficacy of AI-061 in Advanced Solid Tumors AI-061 - Melanoma, Non Small Cell Lung Cancer | Phase 1 | Completed | OncoC4, Inc. | 18 | 2023-07-11 | 2026-09-14 |
| Evaluation of 89Zr-TLX250 PET/CT in Chinese Patients With Indeterminate Renal Masses or Suspected Recurrent Renal Clear Cell Carcinoma 89Zr-Girentuximab - Clear Cell Renal Cell Carcinoma, Suspected Recurrent Renal Clear Cell Carcinoma | Phase 1 | Completed | Telix Pharmaceuticals (Innovations) Pty Limited | 10 | 2023-06-26 | 2023-12-11 |
| A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors SNS-101 (anti-VISTA), Cemiplimab - Solid Tumor, Adult, Advanced Solid Tumor | Phase 1 / Phase 2 | Completed | Sensei Biotherapeutics, Inc. | 98 | 2023-05-31 | 2026-09-02 |
| A Study of CDX-585 in Patients With Advanced Malignancies CDX-585 - Non-small Cell Lung Cancer, Gastric Cancer | Phase 1 | Completed | Celldex Therapeutics | 20 | 2023-05-11 | 2025-06-15 |
| Safety and Toxicity Study of Intravesical Instillation of TARA-002 in Adults with High-grade Non-muscle Invasive Bladder Cancer (Phase 1b) TARA-002 - Non-muscle Invasive Bladder Cancer | Phase 1 | Completed | Protara Therapeutics | 10 | 2023-05-08 | 2025-01-27 |
| A Safety and Efficacy Study Evaluating CTX131 in Adult Subjects With Relapsed or Refractory Solid Tumors CTX131 - Clear Cell Renal Cell Carcinoma, Cervical Carcinoma | Phase 1 / Phase 2 | Completed | CRISPR Therapeutics AG | 19 | 2023-03-13 | 2025-11-26 |
| A Clinical Trial of KVA12123 [TBS-2025] Treatment Alone and in Combination With Pembrolizumab In Advanced Solid Tumors (VISTA-101) KVA12123 - Dose Escalation, KVA12123 Plus Pembrolizumab - Dose Escalation, KVA12123 - Dose Expansion - Cancer, Solid Tumor | Phase 1 / Phase 2 | Completed | Kineta Inc. | 40 | 2023-03-03 | 2026-10-05 |
| Phase 1, First-in-human, Dose-finding and Expansion Study to Evaluate XmAb®808 in Combination With Pembrolizumab in Advanced Solid Tumors XmAb®808, Keytruda® (pembrolizumab) - Head and Neck Squamous Cell Carcinoma, Melanoma Excluding Uveal Melanoma | Phase 1 | Completed | Xencor, Inc. | 60 | 2022-12-14 | 2025-08-07 |
| Study of DF9001 in Patients With Advanced Solid Tumors DF9001, KEYTRUDA® (pembrolizumab) - Solid Tumor, Adult | Phase 1 / Phase 2 | Completed | Dragonfly Therapeutics | 24 | 2022-11-15 | 2025-10-29 |
| Clinical Study to Investigate the Safety and Tolerance of Therapeutic BCG in Postoperative Adjuvant Therapy in Subjects With Moderate to High-risk Non-muscular Invasive Bladder Cancer (NMIBC) BCG for Therapeutic Use - Non-muscular Invasive Bladder Cancer | Phase 1 | Completed | Chengdu CoenBiotech Co., Ltd | 10 | 2022-11-11 | 2024-04-05 |
| A Study of Evorpacept (ALX148) With Enfortumab Vedotin for Subjects With Urothelial Carcinoma (ASPEN-07) Evorpacept, Enfortumab Vedotin - Bladder Cancer, Urothelial Carcinoma | Phase 1 | Completed | ALX Oncology Inc. | 36 | 2022-11-02 | 2025-07-25 |
| Seleno-L Methionine (SLM)-Axitinib-Pembrolizumab Selenomethionine (SLM), Axitinib, Pembrolizumab - Clear Cell Renal Cell Carcinoma, Clear Cell Renal Cell Carcinoma Metastatic | Phase 1 / Phase 2 | Completed | Fernando Maciel Barbosa | 15 | 2022-09-19 | 2026-11-02 |
| Dose Escalation and Expansion Study of WTX-124 as Monotherapy and in Combination With Pembrolizumab (Pembro) in Patients With Selected Advanced or Metastatic Solid Tumors WTX-124, pembrolizumab - Metastatic Solid Tumor, Advanced Solid Tumor | Phase 1 | Completed | Werewolf Therapeutics, Inc. | 156 | 2022-08-15 | 2026-10-09 |
| A Phase 1 in Patients With HLA-A*0201+ and WT1+ Recurrent/Metastatic Cancers CUE-102 - Colorectal Cancer, Gastric Cancer | Phase 1 | Completed | Cue Biopharma | 42 | 2022-06-14 | 2026-01-22 |
| A Phase 1 Dose-escalation Study of UGN-301 in Patients With Recurrent Non-muscle Invasive Bladder Cancer (NMIBC) UGN-301, UGN-201, Gemcitabine - Non-muscle Invasive Bladder Cancer, NMIBC | Phase 1 | Completed | UroGen Pharma Ltd. | 51 | 2022-06-01 | 2026-01-14 |
| A Study of MGC018 in Combination With MGD019 in Participants With Advanced Solid Tumors vobramitamab duocarmazine, lorigerlimab - Advanced Solid Tumor, Castration-Resistant Prostatic Cancer | Phase 1 | Completed | MacroGenics | 31 | 2022-04-19 | 2025-10-14 |
Showing 20 of 512. Sign in to see all of them.
Carcinoma, Renal Cell (283) · Urinary Bladder Neoplasms (170) · Kidney Neoplasms (129) · Carcinoma, Non-Small-Cell Lung (126) · Melanoma (109) · Breast Neoplasms (98) · Neoplasms (85) · Ovarian Neoplasms (85) · Colorectal Neoplasms (75) · Prostatic Neoplasms (64) · Lung Neoplasms (63) · Pancreatic Neoplasms (63) · Stomach Neoplasms (59) · Sarcoma (54) · Neoplasm Metastasis (50)
Female Urogenital Diseases (512) · Female Urogenital Diseases and Pregnancy Complications (512) · Male Urogenital Diseases (512) · Urogenital Diseases (512) · Neoplasms by Site (510) · Urogenital Neoplasms (508) · Urologic Diseases (508) · Neoplasms (427) · Neoplasms by Histologic Type (413) · Neoplasms, Glandular and Epithelial (386) · Kidney Diseases (367) · Carcinoma (353) · Adenocarcinoma (296) · Kidney Neoplasms (242)
pembrolizumab (47) · Nivolumab (37) · Gemcitabine (30) · Everolimus (23) · Cisplatin (18) · Paclitaxel (18) · Bevacizumab (17) · Sorafenib (17) · Sunitinib (16) · pazopanib (14) · temsirolimus (13) · Docetaxel (12) · Carboplatin (11) · Cyclophosphamide (10) · Filgrastim (10)
National Cancer Institute (NCI) (47) · Memorial Sloan Kettering Cancer Center (21) · Novartis Pharmaceuticals (11) · GlaxoSmithKline (9) · Bristol-Myers Squibb (8) · Celldex Therapeutics (8) · Ludwig Institute for Cancer Research (8) · M.D. Anderson Cancer Center (8) · Eli Lilly and Company (7) · Merck Sharp & Dohme LLC (7) · Dana-Farber Cancer Institute (6) · Fred Hutchinson Cancer Center (6) · National Institutes of Health Clinical Center (CC) (6) · Pfizer (6) · Emory University (5)
United States (405) · Canada (39) · United Kingdom (39) · France (37) · Spain (36) · Germany (26) · Australia (25) · Italy (25) · Netherlands (23) · South Korea (22) · Belgium (16) · Japan (14) · China (11) · Denmark (11) · Singapore (9)
Dean F. Bajorin, MD (4) · Brenda Sandmaier (3) · John E. Janik, MD (3) · Robert J. Motzer, MD (3) · Arkadiusz Dudek, MD (2)
PMID 32499241, PMID 19949018, PMID 22002018, PMID 30807645, PMID 31401903, PMID 37496366, PMID 39462179, PMID 41044356, PMID 11410496, PMID 12727829, PMID 15814645, PMID 15928663, PMID 16234526, PMID 16914576, PMID 17395103, PMID 17409436, PMID 17452976, PMID 17893567, PMID 18245546, PMID 18272024, PMID 18281544, PMID 18470481, PMID 18833002, PMID 19075272, PMID 19100600, PMID 19179301, PMID 19192962, PMID 19430790, PMID 19636012, PMID 19706807, PMID 19755389, PMID 20044751, PMID 20068553, PMID 20142724, PMID 20145168, PMID 20179219, PMID 20407240, PMID 20460632, PMID 20797845, PMID 21403127, PMID 21447719, PMID 21633906, PMID 21917625, PMID 21994418, PMID 22129044, PMID 22159179, PMID 22213823, PMID 22259028, PMID 22430088, PMID 22658127
2016 (6), 2019 (6), 2014 (5), P30CA015704 (5), 2015 (4), 2017 (4), U01CA132123 (4), 2009 (3), U01CA062491 (3), U01CA070095 (3), 2018 (2), 2023 (2), P01CA018029 (2), P30CA012197 (2), P30CA014520 (2)